在癌症中,BCL6通过对抗BLIMP1促进了类似干细胞的CD8+ T细胞程序
Qinli Sun1, Dongli Cai2,3, Dingfeng Liu2,3
1Institute for Immunology and School of Medicine, Tsinghua University, Beijing 100084, China.
Science immunology
|October 20, 2023
概括
BCL6 抑制来自原生细胞 (Tprog细胞) 的强有力的细胞毒性 CD8+ T 细胞 (Tterm细胞) 的发展. 向TGF-β-BCL6和IL-2-BLIMP1通路可能会提高癌症免疫治疗的持续性和有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- T细胞生物学T细胞生物学
背景情况:
- 克服CD8+T细胞耗尽对于有效的癌症免疫疗法至关重要.
- 内CD8+T原生细胞 (Tprog细胞) 维持抗瘤反应,但可以分化为终极耗尽的细胞 (Tterm细胞).
- 控制Tprog细胞持久性和分化的外部信号在很大程度上是未知的.
研究的目的:
- 研究转录因子,特别是BCL6在调节CD8+T细胞分化和瘤微环境中的持久性方面的作用.
- 阐明控制Tprog细胞命运的信号通路及其对抗瘤免疫力和免疫疗法的效果的影响.
主要方法:
- 在排水淋巴结和瘤中的瘤特异性CD8+ T细胞中分析BCL6表达.
- 研究了BCL6缺乏对Tprog细胞持久性和瘤控制的影响.
- 研究了TGF-β-SMAD2和IL-2-STAT5信号通路对BCL6和BLIMP1表达的调节作用.
- 评估了PRDM1 (BLIMP1) 缺陷对Tprog细胞程序和抗PD-1疗法的疗效的影响.
主要成果:
- 在TCF1.1.下游的Tprog细胞中,BCL6抑制了瘤特异性Tterm细胞的生成.
- 缺乏Bcl6会减少Tprog细胞的持久性,从而影响长期的瘤控制.
- BCL6表达通过TGF-β-SMAD2信号升调,并通过IL-2-STAT5信号降调,对抗BLIMP1.
- 缺乏PRDM1促进了Tprog细胞程序,并增强了抗PD-1疗法的疗效.
结论:
- TGF-β-BCL6和IL-2-BLIMP1信号通路对抗性调节抗瘤CD8+T细胞的分化和功能.
- 针对这些途径,特别是通过调节BCL6活性,有望开发更有效,更持久的癌症免疫疗法.
相关概念视频
T Cell Activation and Clonal Selection
764
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
764
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Renewal of Intestinal Stem Cells
2.6K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.6K


